# OnCo record dinutuximab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dinutuximab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dinutuximab" ;
  schema:name "Dinutuximab (ch14.18) / dinutuximab beta"@en ;
  schema:description "The antibody that raised cure rates in high-risk childhood neuroblastoma by about 20 points when given after transplant with immune boosters and retinoid."@en ;
  schema:url <https://onco.cc/drugs/dinutuximab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Dinutuximab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21011236> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dinutuximab/%20dinutuximab%20beta> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-GD2, chimeric)" ;
  schema:alternateName "Unituxin / Qarziba (EU)" ;
  onco:approval "US 2015: High-risk neuroblastoma after at least partial response to induction, with GM-CSF, IL-2 and isotretinoin", "EU 2017: Dinutuximab beta: high-risk neuroblastoma after induction/transplant; relapsed/refractory disease" ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/gd2/> ;
  onco:companies <https://onco.cc/companies/united-therapeutics/> ;
  onco:terms <https://onco.cc/terms/adcc/> ;
  onco:trials <https://onco.cc/trials/anbl0032/>, <https://onco.cc/trials/hr-nbl1/> .